Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 8:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–5 of 5 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: FGFR3 Genetic Alterations Clear all

Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

NCT01752920

View directory record Official record

Conditions: Solid Tumor
Interventions: Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose range, Derazantinib at recommended phase 2 dose (RP2D); Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years and older

Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 8
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Detroit, Michigan + 5 more

Source: ClinicalTrials.gov public record

Updated Jun 4, 2023 · Synced May 21, 2026, 8:11 PM EDT

Terminated Phase 3 Interventional Results available

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

NCT04197986

View directory record Official record

Conditions: Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer
Interventions: Infigratinib, Placebo; Drug
Lead sponsor: QED Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years and older

Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 47
States / cities: Tucson, Arizona • Duarte, California • Loma Linda, California + 39 more

Source: ClinicalTrials.gov public record

Updated Mar 12, 2024 · Synced May 21, 2026, 8:11 PM EDT

Completed Phase 2 Interventional Results available

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

NCT02272998

View directory record Official record

Conditions: Malignant Neoplasm
Interventions: ponatinib hydrochloride, laboratory biomarker analysis; Drug · Other
Lead sponsor: Sameek Roychowdhury; Other
Eligibility: 18 Years and older

Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Columbus, Ohio

Source: ClinicalTrials.gov public record

Updated Mar 23, 2025 · Synced May 21, 2026, 8:11 PM EDT

Active, not recruiting Phase 1Phase 2 Interventional

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

NCT06777316

View directory record Official record

Conditions: Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Amplification, FGFR2 Gene Short Variants, FGFR3 Gene Fusion/Rearrangement, FGFR3 Gene Amplification, FGFR3 Gene Short Variants, FGFR2 Genetic Alterations, FGFR3 Genetic Alterations, Advanced Solid Tumors
Interventions: CGT4859; Drug
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 12
States / cities: Palo Alto, California • Jacksonville, Florida • Tampa, Florida + 9 more

Source: ClinicalTrials.gov public record

Updated Apr 16, 2026 · Synced May 21, 2026, 8:11 PM EDT

Terminated Phase 1Phase 2 Interventional

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

NCT05363605

View directory record Official record

Conditions: Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma, Susceptible FGFR3 Genetic Alterations, FGFR3, FGFR3 Overexpression, FGFR3 Receptor, FGFR3 Protein Overexpression, Ovarian Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Lung Cancer, Gastric Cancer
Interventions: [225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab; Drug · Biological
Lead sponsor: Fusion Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Duarte, California • San Francisco, California • Iowa City, Iowa + 1 more

Source: ClinicalTrials.gov public record

Updated Dec 18, 2023 · Synced May 21, 2026, 8:11 PM EDT